Clinicogenomic analysis of EGFR-mutant lung tumors identifies Rb pathway inactivation as a hallmark of squamous transformation

Submitted by Anonymous on

AbstractHistologic transformation to lung squamous cell carcinoma (LUSC) is an underrecognized mechanism of resistance in epidermal growth factor receptor (EGFR)–mutant lung adenocarcinoma (LUAD). Although AKT and MYC activation have been linked to LUSC features, the clinicogenomic determinants of this transformation...

Case Report: Neoadjuvant chemoimmunotherapy achieving pathological complete response in two cases of stage III EGFR-mutant NSCLC with high PD-L1 expression

Submitted by Anonymous on

Abstract Resectable locally advanced EGFR-mutant non-small cell lung cancer (NSCLC) represents a distinct therapeutic challenge. Owing to an inherently immunosuppressive tumor microenvironment-frequently characterized by absence of or low PD-L1 expression and sparse CD8+ tumor-infiltrating lymphocytes-patients with EGFR alterations have been...

Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial

Submitted by Anonymous on

ArticlesOnline firstJune 16, 2026Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trialProf Ziming Li, MDa,† ∙ Prof Jie Hu, MD PhDb,c,† ∙ Prof Jianhua Chen, MDd ∙ Prof Yan...

Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non–Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial

Submitted by Anonymous on

: The HARMONi-A Randomized Clinical Trial : The HARMONi-A Randomized Clinical Trial : Research Summary : Research Summary Key Points Question Does adding ivonescimab to chemotherapy improve overall survival in patients with epidermal growth factor receptor (EGFR) gene variant non–small...

Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non–Small Cell Lung Cancer: Research Summary

Submitted by Anonymous on

: Research Summary : Research Summary This study assessed whether adding ivonescimab, a bispecific antibody, to chemotherapy improves overall survival for patients with advanced epidermal growth factor receptor (EGFR) gene variant nonsquamous non–small cell lung cancer (NSCLC) after disease progression...

ArriVent BioPharma (AVBP) Stock Valuation After Growing Expectations For EGFR Firmonertinib Trials

Submitted by Anonymous on

AdvertisementEGFR Market Attention Puts Focus on ArriVent BioPharma Recent commentary on the EGFR inhibitor market, highlighting precision medicine trends and ArriVent BioPharma (AVBP) firmonertinib trials in non small cell lung cancer, has pushed this clinical stage stock back onto investor...

B7 homolog 3-targeted CAR-T cells secreting EGFR T-cell engagers for improved control of glioblastoma progression

Submitted by Anonymous on

Abstract Glioblastoma (GBM) is the most aggressive primary malignant brain tumor, and while chimeric antigen receptor-T (CAR-T) cell therapy has shown promise, its efficacy remains limited by antigen heterogeneity and immune escape. Here, we investigated the expression of B7 homolog...

EGFR Inhibitors Market to Witness Upsurge in Growth at a CAGR of 7.9% During the Forecast Period (2026-20

Submitted by Anonymous on

Key Takeaways from the EGFR Inhibitors Market Report Discover which EGFR drugs will lose patent exclusivity @ https://www.delveinsight.com/report-store/egfr-market-forecast Key Factors Driving the EGFR Inhibitors Market Aparna Thakur, an oncology expert at DelveInsight, said that Exon 20 insertion has emerged as...

EGFR Inhibitors Market to Witness Upsurge in Growth at a CAGR of 7.9% During the Forecast Period (2026-2036) Owing to the Entry of Next-generation TKIs, ADCs, and Combination Strategies with Immunotherapy| DelveInsight

Submitted by Anonymous on

The outlook for the EGFR inhibitor market continues to be highly promising, supported by the increasing adoption of precision medicine in oncology and the broader use of targeted therapies across various cancer indications. Additionally, the expected launch of therapies such...

Erlotinib plus bevacizumab in EGFR-amplified metastatic solid tumors: results from the KOSMOS I, II study of molecular profiling–guided therapy in advanced cancers

Submitted by Anonymous on

AbstractPurpose Epidermal growth factor receptor (EGFR) amplification remains a controversial therapeutic biomarker. We report outcomes of erlotinib plus bevacizumab (E + B) in patients with EGFR-amplified metastatic solid tumors. Methods Patients with metastatic solid cancer who had progressed after standard therapies and...

Subscribe to Newsfeed